Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to Thomas A Luger  1 , Adelaide A Hebert  2 , Andrea L Zaenglein  3 , Jonathan I Silverberg  4 , Huaming Tan  5 , William C Ports  5 , Michael A Zielinski  6 Affiliations Expand Affiliations 1 Department of Dermatology, University Hospital Münster, Munster, Germany. 2 Department of Dermatology, UTHealth McGovern Medical School-Houston, 6655 Travis Street, Suite 980, Houston, TX, 77030, USA. Adelaide.A.Hebert@uth.tmc.edu. 3 Department of Dermatology, Pennsylvania State University, Hershey, PA, USA. 4 Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 5 Pfizer Inc., Groton, CT, USA. 6 Pfizer Inc., Collegeville, PA, USA. PMID: 35292919 PMCID: PMC8940811 DOI: 10.1007/s40272-021-00490-y Free PMC article Item in Clipboard

Abstract

Objectives: This post hoc analysis of pooled data from two phase III studies (AD-301: NCT02118766; AD-302: NCT02118792) explored the efficacy and safety of crisaborole ointment, 2%, a nonsteroidal phosphodiesterase 4 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in pediatric patients (aged 2 to < 18 years) only, stratified by baseline characteristics.

Methods: Pediatric patients with mild or moderate AD per Investigator's Static Global Assessment (ISGA) and percentage of treatable body surface area (%BSA) ≥ 5 at baseline were assessed. Crisaborole or vehicle (2:1 randomization ratio) was applied twice daily for 28 days. Of the 1313 pediatric patients included in this study, 874 received crisaborole and 439 received vehicle. ISGA success was defined as clear (0) or almost clear (1) with ≥ 2-grade improvement from baseline. Efficacy and safety were stratified by age group, sex, baseline ISGA, baseline %BSA per published severity strata, and prior AD therapy.

Results: Overall, the proportions of crisaborole-treated and vehicle-treated pediatric patients with ISGA success at week 4 were 32.5 and 21.5%, respectively. ISGA success rates at day 29 (week 4) were generally higher in crisaborole-treated (21.9-38.1%) than vehicle-treated (15.7-26.9%) patients across subgroups. Rates of treatment-related application site pain were 2.4-10.1% for crisaborole-treated patients and 0.6-2.2% for vehicle-treated patients across subgroups. No new safety concerns were noted in any patient subgroup.

Conclusion: Crisaborole improved global disease severity and was reasonably well tolerated across all pediatric baseline characteristic subgroups. Application site discomfort was greater with crisaborole than with vehicle, but few patients discontinued treatment.

Gov registration numbers: NCT02118766; NCT02118792 (registration date: April 21, 2014).

Conflict of interest statement

Thomas A. Luger has served as an investigator for Pfizer, AbbVie, Celgene, Eli Lilly, LEO Pharma, Menlo Therapeutics, Novartis, and Sandoz; served as a member of scientific advisory boards for Pfizer, AbbVie, Argenx, Celgene, Ceres Pharma, Galderma, Eli Lilly, Janssen-Cilag, La Roche-Posay, LEO Pharma, Menlo Therapeutics, Mylan/Meda AB, Novartis, Pierre Fabre, Piqur Therapeutics, Sandoz, Sanofi-Aventis, and Symrise; and has received funding from Pfizer, AbbVie, Celgene, Janssen-Cilag, Merck Sharp & Dohme, Mylan/Meda AB, Novartis, and Wolff Laboratories. Adelaide A. Hebert discloses that research funding was paid to UTHealth McGovern Medical School from Pfizer, Anacor, Arcutis, Cutanea, Brickell, Dermira, GlaxoSmithKline, and Novan. She has received honoraria as a member of data safety monitoring boards for Bausch, GlaxoSmithKline, and Regeneron-Sanofi and has received honoraria from Pfizer, Biofrontera, Cutanea, Dermavant, Dermira, Galderma, Eli Lilly, Leo Pharma, Ortho Dermatologics, Pierre Fabre, and Verrica. Andrea L. Zaenglein has served as an investigator for AbbVie, Arcutis, Dermavant, Incyte, and Pfizer and as a consultant for Cassiopea and Verrica. Jonathan I. Silverberg has served as an investigator for Celgene, Eli Lilly, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, and Regeneron-Sanofi; as a consultant for Pfizer, AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermira, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; and as a speaker for Regeneron and Sanofi. Huaming Tan and Michael A. Zielinski are employees of and stockholders in Pfizer Inc. William C. Ports was an employee of and stockholder in Pfizer Inc. at the time of this analysis.

© 2022. The Author(s).

Figures

Fig. 1

Proportions of patients achieving ISGA successa at day 29 (week 4) in the pediatric population (aged 2 to < 18 years) (AD-301 + AD-302 pooled). %BSA percentage of treatable body surface area, AD atopic dermatitis, CI confidence interval, ISGA Investigator’s Static Global Assessment. aDefined as an ISGA of clear (0) or almost clear (1) with ≥ 2-grade improvement from baseline. bDefined as any prior use of systemic corticosteroids, topical corticosteroids, or topical calcineurin inhibitors for the treatment of AD within 90 days of study screening

Fig. 2

Proportions of patients achieving ISGA of clear or almost clear at day 29 (week 4) in the pediatric population (aged 2 to %BSA percentage of treatable body surface area, AD atopic dermatitis, CI confidence interval, ISGA Investigator’s Static Global Assessment. aDefined as any prior use of systemic corticosteroids, topical corticosteroids, or topical calcineurin inhibitors for the treatment of AD within 90 days of study screening

Fig. 3

Proportions of patients achieving SPS successa at week 4 in the pediatric population (aged 2 to < 18 years) (AD-301 + AD-302 pooled). %BSA percentage of treatable body surface area, AD atopic dermatitis, CI confidence interval, ISGA Investigator’s Static Global Assessment, SPS Severity of Pruritus Scale. aDefined as a weekly average SPS score ≤ 1 with ≥ 1-point improvement from baseline. bDefined as any prior use of systemic corticosteroids, topical corticosteroids, or topical calcineurin inhibitors for the treatment of AD within 90 days of study screening